Printer Friendly

RESULTS OF HUMAN PHASE I TRIAL OF CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT REPORTED

 WORCESTER, Mass., Jan. 25 /PRNewswire/ -- A clinical investigator from Memorial Sloan-Kettering Cancer Center presented data on Jan. 23 at a meeting of the New York Academy of Sciences, entitled Specific Immunotherapy of Cancer with Vaccines, on the results of a Phase I clinical trial involving the use of a proprietary vaccine adjuvant developed by Cambridge Biotech Corporation (NASDAQ: CBCX).
 The study assessed methods of augmenting antibody response to melanoma ganglioside vaccines combined with various adjuvant compounds in a total of 30 post-surgical melanoma patients.
 Cambridge Biotech's QS-21 adjuvant, trade named Stimulon(tm) adjuvant, was used in combination with a cancer antigen prepared by Biomira Inc. and administered to six of the 30 patients. The remaining patients received ganglioside formulations containing other adjuvants. The immunotherapeutic containing QS-21 elicited antibody responses in all six patients, a result unequaled by any other vaccine in the study; it also produced a longer-lasting class of antibodies at concentrations greater than all other adjuvanted immunotherapeutics tested.
 Dr. Philip O. Livingston, who conducted the study, said of the trial results, "We are enthusiastic about the results of this initial trial, which demonstrated that a vaccine containing the QS-21 adjuvant is both safe and active in humans."
 Commenting on the results, Dr. Gerald A. Beltz, Cambridge Biotech's director of research, said, "This clinical trial marks the first use of Cambridge Biotech's QS-21 adjuvant in humans, and we are pleased to report that the safety and high antibody titers elicited in numerous animal studies over the years were replicated in humans.
 Cambridge Biotech Corporation is a leading diagnostics and therapeutics company involved in infectious diseases. The company is developing vaccines, adjuvants and diagnostics for humans and animals.
 -0- 1/25/93
 /CONTACT: Peter P. Hartman, Vice President-Finance and Chief Financial Officer, Cambridge Biotech Corp., 508-797-5777 ext. 550 or Gerald A. Beltz, Director of Research, Cambridge Biotech Corp. 508-797-5777 ext. 537/
 (CBCX)


CO: Cambridge Biotech Corporation ST: Massachusetts IN: MTC SU:

TM -- NE004 -- 8240 01/25/93 08:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 25, 1993
Words:330
Previous Article:EPA ENFORCEMENT OF CFC REGS HEATS UP HVAC MARKET: DEFENSE CONTRACTOR WINS COMMERCIAL SUCCESS
Next Article:PERSEPTIVE BIOSYSTEMS, INC. LAUNCHES AUTOPILOT FOR PILOT-SCALE PURIFICATION WITH FIRST SYSTEM SALE
Topics:


Related Articles
CAMBRIDGE BIOTECH CORPORATION SIGNS INTENT TO ACQUIRE MINORITY STAKE IN IMMUCELL CORPORATION
CAMBRIDGE BIOTECH CORPORATION AND PASTEUR MERIEUX IN INFLUENZA VACCINE PARTNERSHIP
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
CAMBRIDGE BIOTECH CORPORATION AND GENENTECH, INC. AGREE TO VACCINE ALLIANCE
CAMBRIDGE BIOTECH REPORTS 1992 RESULTS
CAMBRIDGE BIOTECH LICENSES ITS STIMULON ADJUVANT TO AMERICAN CYANAMID
CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT IN PHASE I TRIAL WITH GENENTECH HIV-1 VACCINE
WYETH-AYERST BEGINS TESTING LIPOSOMAL FLU VACCINE; THE LIPOSOME COMPANY'S NEW ADJUVANT MAY BOOST PROTECTION
Aquila Announces Initial Results Of Phase II Clinical Trial Of Quilimmune-P(TM) To Prevent Pneumococcal Infections.
Aquila Announces Preliminary Results From Phase I Clinical Trial Of Quilimmune-M(TM) Malaria Vaccine.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters